Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

NCT01846273 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

321

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration
Polypoidal Choroidal Vasculopathy

Interventions

DRUG: Ranibizumab
DRUG: Verteporfin PDT
DRUG: Sham PDT

Sponsor

Novartis Pharmaceuticals